|
|
|
|
Thursday, August 15, 2019
Onconova Therapeutics (ONTX)
Multiple Value Driving Inflection Points in Near to Medium Term Horizon
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focused on discovering and developing small molecule inhibitors to treat cancer. The lead product candidate rigosertib is in Phase 3 clinical trial for patients with higher risk myelodysplastic syndromes (MDS). The company has a license agreement with SymBio Pharmaceuticals Limited, development, and commercialization agreement with Pint International; and a license and collaboration agreement with HanX Biopharmaceuticals. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Ahu Demir, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Onconova’s main focus is INSPIRE. The company is on track to complete enrollment of Phase 3 study (INSPIRE) with rigosertib, a RAS pathway inhibitor, for the treatment of 2nd line high-risk myelodysplastic syndrome (HR-MDS). Completion of enrolment is expected in H2 2019, data readout to follow in H1 2020.
- Key Value Driving Catalysts. Although topline data readout from INSPIRE trial remains as the major milestone for Onconova, we believe achieving the following milestones will generate inflection points for the company; 1) completion of enrollment in INSPIRE study in H2 2019, 2) finalization of…
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.